Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Stoke Therapeutics, Inc.NASDAQ: STOK

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 43.4% from a year ago

Cash & equivalents stood at $155.66M at the end of Q1 FY2026, down 43.4% from a year earlier and up 84.8% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.

Context

  • Cash & equivalents amounted to 35.1% of total assets at the end of Q1 FY2026, down 32.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -43.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$155.66M+84.8% QoQ
Last fiscal yearDec 2025
$84.22M-34.2% YoY
Year agoMar 2025
$274.82M-43.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.4%——
1 year-34.2%——
3-year CAGR-9.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
84.22M USD
Year-over-year change
-34.2%
4-year CAGR
-12.7%

Cash & Equivalents vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -43.4% is the 6th highest of 7, against a peer median of -17.3%.
  • Cash & equivalents amounts to 35.1% of total assets for STOK, versus a peer median of 13.0%.
STOK Competitors
Cash & Equivalents for STOK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
WVEWave Life Sciences Ltd.Mar 2026$544.59M USD+124.0%+89.5%93.3%
IONSIonis Pharmaceuticals, Inc.Sep 2026$296.3M USD-12.4%+10.4%10.2%
BEAMBeam Therapeutics Inc.Jun 2026$219.83M USD-22.1%+8.2%15.9%
STOKStoke Therapeutics, Inc.Mar 2026$155.66M USD-43.4%-9.5%35.1%
PRQRProQR Therapeutics N.V.Mar 2026€81.17M EUR-43.2%-0.9%81.9%
DSGNDesign Therapeutics, Inc.Mar 2026$12.77M USD-6.6%-14.0%5.5%
SLNSilence Therapeutics plcMar 2026$5.66M USD-91.3%-41.0%4.9%
Peer median (excluding STOK) —-17.3%+3.7%13.0%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents144.9M113.56M191.44M127.98M84.22M
Short-term Investments74.92M116.04M9.95M88.92M200.45M
Net Receivables132K588K64K700K7.91M
Inventory00000
Other Current Assets2.33M2.96M2.56M4.04M4.39M
Total Current Assets229.22M244.07M215.34M232.76M305.7M
Property, Plant & Equipment (Net)9.08M11.43M12.43M8.25M6.25M
Goodwill00000
Intangible Assets00000
Long-term Investments00029.82M0
Tax Assets00000
Other Non-current Assets569K569K569K721K106.49M
Total Non-current Assets9.65M12M13M38.8M112.73M
Total Assets238.87M256.07M228.34M271.56M418.43M
Account Payables2.39M766K1.7M2.5M4.94M
Short-term Debt00000
Tax Payables00000
Deferred Revenue014.88M15.31M18.99M11.9M
Other Current Liabilities5.92M6.26M6.47M8.44M15.04M
Total Current Liabilities17.14M31.39M30.82M40.06M57.88M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)036.86M33.07M06.96M
Other Non-current Liabilities3.95M2.97M4.88M2.48M1.14M
Total Non-current Liabilities3.95M39.82M37.96M2.48M8.1M
Total Liabilities21.09M71.22M68.78M42.53M65.98M
Common Stock4K4K5K5K5K
Retained Earnings(196.08M)(297.15M)(401.85M)(490.83M)(497.72M)
Accumulated OCI(168K)(1.18M)(24K)(151K)543K
Other Stockholders Equity00000
Minority Interest00000
Total Equity217.78M184.85M159.57M229.02M352.46M
Total Debt1.51M2.36M2.06M2.32M3.01M
Net Debt(143.39M)(111.2M)(189.38M)(125.66M)(81.21M)

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.